Evidence map›Paper›PMID 40542086›Full record

ArticleGene therapy2026

Mixture design as a tool for improving full-to-empty particle ratios across various GOIs in rAAV production.

Konstantina Tzimou, Pol Hulsbus-Andreu, Ece Bahar Yildirim, Lars K Nielsen, Jesús Lavado-García

Abstract read
In one paragraph

Article in Gene therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Konstantina TzimouThe Novo Nordisk Foundation Center for Biosustainability, Technical University of Denmark, Lyngby, Denmark.ORCID 0009-0003-7174-2714
Pol Hulsbus-AndreuThe Novo Nordisk Foundation Center for Biosustainability, Technical University of Denmark, Lyngby, Denmark.
Ece Bahar YildirimDTU Bioengineering, Technical University of Denmark, Lyngby, Denmark.
Lars K NielsenThe Novo Nordisk Foundation Center for Biosustainability, Technical University of Denmark, Lyngby, Denmark.ORCID 0000-0001-8191-3511
Jesús Lavado-GarcíaThe Novo Nordisk Foundation Center for Biosustainability, Technical University of Denmark, Lyngby, Denmark. jlavgar@dtu.dk.ORCID 0000-0001-9993-6332

Funding

Novo Nordisk Fonden (Novo Nordisk Foundation) NNF14OC0009473
6 · The paper itself

Abstract

Optimization of recombinant adeno-associated virus (rAAV) production is essential for effective gene therapy applications. However, multiple factors affect the rAAV productivity in mammalian cells, and often they interact with each other, making the optimization process highly challenging. In our previous work, we showed how coupling mixture design (MD) with face-centered central composite design (FCCD) was the most suitable design of experiments (DOE) approach for optimizing rAAV2 productivity and cell viability. In this study, we built on this method and demonstrate that combining MD with FCCD can be used to optimize the percentage of full capsids in rAAV2 upstream preparation. Additionally, we investigate the influence of the gene of interest (GOI) on the optimal conditions for viral particle production and packaging efficiency. By integrating MD and FCCD methodologies, we achieved an improvement of almost 100-fold in Log(Vp) in the case of egfp-expressing rAAV, and a 12-fold increase in bdnf-expressing full rAAV capsids, suggesting that this combined approach is a versatile and effective strategy for optimizing rAAV production processes. These findings emphasize the need for a comprehensive understanding of the factors influencing rAAV production to enhance the efficiency and efficacy of viral vector applications in gene therapy.

Indexed as

DependovirusGenetic VectorsAnimalsCapsidGenetic TherapyGreen Fluorescent ProteinsHEK293 CellsHumansGreen Fluorescent Proteins

Identifiers

PMID40542086
PMCPMC12932106

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.